As a sign that digital clinical trials are becoming the norm and not the exception, Veeva Systems has signed up 40 CROs to use its suite of clinical trial management tools as part of efforts to provide more efficient communications and operations.
Among the CROs that will begin using the Veeva Vault clinical trial systems are Labcorp, Parexel and Thermo Fisher’s PPD clinical trial division, Veeva said in an Oct. 17 press release.
The Vault system was also chosen by more than 120 trial sponsors, nine of which rank in the top 20 global pharmaceutical organizations, the company said. The system was designed with metrics that allow CROs to improve the management of their study performances and increase transparency for sponsors. Vault also makes it easier for sponsors to collaborate and share information in real time.
“Veeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs,” Veeva Vault Vice President Henry Galio said in the release. “As more companies advance trial operations with Veeva, sponsors, CROs and sites can work closer together to drive faster study endpoints and accelerate subject enrollment in trials.”
Cloud software providers like Veeva have experienced rapid growth as virtual or hybrid clinical trials became necessary during the COVID-19 pandemic. The trend for virtual trials is expected by many analysts to become more of the norm in the coming years.
In a late 2021 survey conducted by trial software provider Science 37, about 77% of respondents planned to run a hybrid trial in the next 12 months compared to 59% from the previous year. A similar survey by Veeva conducted around the same time found 87% of sponsors and CROs were planning to conduct trials digitally versus 28% that did so prior to the pandemic.